📨 A new #CIOMS Newsletter is available! Keep informed of the latest updates from the Secretariat, international events, working group meetings, plus new reports on real-world data and real-world evidence, SCARS, and the CIOMS glossary of ICH terms 👉 ow.ly/v1BH50SsLc0

Signals of adverse drug reactions can be based on different study designs. Daniele Sartori sat down in the Research Corner to discuss the findings of his scoping review and highlight the evidence base and features of ADR reports. Full video 📺 youtu.be/GhTmiGjLLyw

Is age the best measure to fully capture the complexity of increased ADR risk in older patients? Giovanni Furlan and Jennifer Stevenson argue that we should consider frailty in #pharmacovigilance practices instead. Learn more in #UppsalaReports👇 ow.ly/T0CZ50RN2J2

Looking for some tips and tricks for your 2024 #MedSafetyWeek campaign? Three campaign veterans share their insights about #pharmacovigilance communications in this #DrugSafetyMatters episode. Listen to what Frieda Shigwedha of Namibia🇳🇦 has to say 👉 ow.ly/8Fga50Q6VCj

📰 A new issue of the World Health Organization (WHO) pharmaceuticals newsletter has arrived! Keep up to date with the latest information on the safety of medicinal products and regulatory actions taken by authorities worldwide. Read more at the link below👇 who.int/publications/i…

🎥 Patient narratives help paint the complete picture of adverse events from medicines and vaccines. Shanthi Pal, Team Lead of Pharmacovigilance at World Health Organization (WHO), describes how #PatientSafety is at the heart of the WHO PIDM and #pharmacovigilance in the film below👇

Detecting duplicates is just one cog in the #pharmacovigilance machine. Jim Barrett outlines how we're utilising #MachineLearning and new methods to compare reports to better detect side effects at UMC💡     Read more in #UppsalaReports👇 uppsalareports.org/articles/weedi…

ADRs are usually studied as drug-event combinations. Yet this approach may be too simplistic when it comes to complex reactions. For #UppsalaReports, Michele Fusaroli proposes new conceptual frameworks to delve deeper into the intricacies of side effects👇 uppsalareports.org/articles/updat…

In JMIR Publications Medical Informatics, Daniele Sartori and coauthors utilise #MachineLearning and time-series analyses to determine what factors influence the quality of adverse event reports submitted to #VigiBase in Malaysia🇲🇾. Open access👇 doi.org/10.2196/49643

🎥 What is a signal? All medicines and vaccines come with benefits and risks. We explore the significance of #pharmacovigilance and the signal detection process at UMC, including screening #VigiBase, collaborating with World Health Organization (WHO) and WHO PIDM members in the film below👇

Join UMC's Niklas Norén at International Society for Pharmacoepidemiology #ISPEAnnual2024 for a pre-conference course on signal detection in #pharmacovigilance and an oral presentation: 📆 Sunday, 25 August, and Tuesday, 27 August 📍 Estrel Congress Centre, Berlin🇩🇪 All event info 👉 2024ispe.eventscribe.net

The safety of #OrphanDrugs is hard to monitor as they target rare diseases afflicting small patient populations. However, an initiative led by the SFDA aims to improve this. Find out more in this #UppsalaReports article👇 uppsalareports.org/articles/safet…

Join UMC's Oskar Gauffin at International Society for Pharmacoepidemiology #ISPEAnnual2024 to explore applying #multimodal approaches to signal detection, validation, and evaluation: 📆 Monday, 26 August 🕙 15:30–17:00 CEST 📍 Estrel Congress Centre, Berlin🇩🇪 All event info 👉 2024ispe.eventscribe.net

To genotype or not to genotype, that is the question🧬 Our #genotype, the collective term for our whole set of genes and genetic variants, can contribute 15 to 95% of how we react to medicines. Why is this the case, and when is genetic testing necessary to avoid the risk of

#VigiBase has grown in size and coverage, with increasing contributions from geographic regions and reporters since 2010. UMC researchers describe global patterns and trends of AE reporting to the global database in a new poster, presented at #ISPEAnnual2024. Download the PDF 👉

As pregnant individuals are generally excluded from clinical trials, robust post-marketing surveillance is necessary. UMC researchers are at #ISPEAnnual2024 presenting their new poster, which outlines how an #algorithm can facilitate the identification of pregnancy cases in

Jim Barrett joins us in the latest #UppsalaReports Long Reads to discuss his article on UMC's duplicate detection algorithm and our work to develop artificial intelligence #AI resources for #pharmacovigilance. Listen now 🎧 ow.ly/j3W450T8AgC

🎥 Quality standardised data is key to ensuring the safety of medicines and vaccines. Mary Joice tells us how VigiFlow has helped FDA Philippines to collect data, manage ADRs and AEFIs, and make good regulatory decisions. Learn more about #VigiFlow 👉 ow.ly/r1Wx50TfkR6

🌍💙 Join us for ISoP Patient Safety Day 2024! Mark your calendars for September 12-13 and participate in this free online event #ISoPPSD2024 📅 When: 12-13 September 2024 💻 Where: Online ISoP Online 🎟 Cost: FREE! 🔗 Register Here: forms.gle/SzkL4Vb2Bhz9sW…

📚 New release – The 75th anniversary edition of the #CIOMS Cumulative Glossary with Focus on Pharmacovigilance. This glossary is an organised collection of the terms and definitions included in published CIOMS Working Group reports. Download your copy👇 cioms.ch/publications/p…